Skip to content

CAR-T cell in pediatric patients with relapse/refractory T-lineage acute lymphoblastic leukemia and lymphoma

CAR-T cell in pediatric patients with relapse/refractory T-lineage acute lymphoblastic leukemia and lymphoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113011
Enrollment
Unknown
Registered
2025-11-24
Start date
2025-06-10
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapse/refractory T-lineage acute lymphoblastic leukemia and lymphoma

Interventions

Sponsors

Shanghai Children's Medical Center Affiliated to School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 35 Years

Inclusion criteria

Inclusion criteria: Patients with disease onset at age < 35 years, with confirmed presence of experimentally validated targets such as CD7, CD99, CD1a, CCR9, etc. Patients must meet at least one of the following criteria: 1. Newly diagnosed patients confirmed as meeting the standard definition of refractoriness for T-lineage malignancies following chemotherapy. 2. Newly diagnosed patients with disease progression during chemotherapy, indicating poor anticipated chemotherapy response. 3. Patients with one or multiple relapses, supported by clear evidence of residual tumor. 4. Patients with disease relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT). 5. Patients who are not candidates for cure with current modalities including surgery, radiotherapy, or chemotherapy.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria will be excluded from participation in this study: 1. Age at disease onset > 35 years; 2. Expected survival period 2.5 mg/dL; ALT/AST > 5× upper limit of normal (ULN); total bilirubin > 2 mg/dL. 7. Presence of uncontrolled active infection. 8. Active hepatitis B or C, or HIV infection. 9. Lost to follow-up within < 3 months after treatment. 10. Failure to provide informed consent or without approval from the Ethics Committee. 11. Presence of other systemic diseases that may interfere with the study. 12. Any other condition deemed by the investigator as grounds for exclusion.

Design outcomes

Primary

MeasureTime frame
Cytotoxicity;MRD;

Secondary

MeasureTime frame
CAR-T cell expansion and persistence;

Countries

China

Contacts

Public ContactBenshang Li

Shanghai Children's Medical Center Affiliated to School of Medicine, Shanghai Jiaotong University

leebenshang@hotmail.com+86 181 0189 3712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026